Bupleurum Flacutum

Bupleurum flacutum  Linn.

1. Taxonomic, Nomenclature & Therapeutic Summary Table

Botanical Attribute Pharmacognostic & Therapeutic Specification
Family Umbelliferae; Apiaceae.
Habitat The Himalayas from Kashmir to Bhutan and the Khasi Hills, at 1,000–4,000 m.
English Hare’s Ear.
Folk Shingu (Himachal Pradesh), Sipil (Punjab), Thaanyo (Garhwal).
Action Roots—anti-inflammatory, haemolytic, antipyretic. Used in inflammations, muscle stiffness, neurosis, pain and pyrexia. Roots resolve inflammations of costal margin and diaphragm.
Key Application Extracts have been used for the treatment of chronic hepatitis, nephrotic syndrome and auto-immune diseases (WHO.).
Taxonomic Cohort Genus Bupleurum (1 documented species); Family Umbelliferae (42 documented species).

2. Classical Nomenclature, Taxonomy & Biogeographical Context

Bupleurum flacutum (taxonomically cited with authority Linn.) is an established medicinal plant species in Indian materia medica. It is classified under the botanical family Umbelliferae; Apiaceae (primary family classification: Umbelliferae), placing it within a well-defined chemotaxonomic group of medicinal flora. Within botanical taxonomy, this taxon is cataloged directly under its primary accepted binomial without secondary botanical synonyms. Biogeographically, its documented habitat and ecological distribution span: The Himalayas from Kashmir to Bhutan and the Khasi Hills, at 1,000–4,000 m.

Across classical and vernacular Indian systems of medicine, Bupleurum flacutum is recognized under distinct polyglot nomenclature: in English botanical and trade usage as Hare’s Ear; in regional Indian folk and vernacular ethnobotany as Shingu (Himachal Pradesh), Sipil (Punjab), Thaanyo (Garhwal). Romanized Sanskrit and Ayurvedic spellings follow standard National Academy of Ayurveda (Rashtriya Ayurveda Vidyapeeth) transliteration conventions, using double vowels to preserve authentic classical pronunciation across regional medical traditions.

3. Therapeutic Actions, Phytochemistry & Pharmacological Profile

In therapeutic and clinical pharmacognosy, the primary recorded actions and clinical indications of Bupleurum flacutum are: Roots—anti-inflammatory, haemolytic, antipyretic. Used in inflammations, muscle stiffness, neurosis, pain and pyrexia. Roots resolve inflammations of costal margin and diaphragm. These traditional and clinical attributes reflect the plant part-specific pharmacological profile documented across classical Indian treatises and modern herbal pharmacopoeias. Furthermore, international and national regulatory monographs highlight its validated key clinical application: Extracts have been used for the treatment of chronic hepatitis, nephrotic syndrome and auto-immune diseases (WHO.).

Experimental phytochemistry, active chemical constituents, and pharmacological screening studies reported for Bupleurum flacutum establish the following evidence base: Therapeutic properties are attributed to saikoside or saikosaponins (yield from roots 2.06–3.02%), a complex mixture of triterpenic saponins. Saponin content varies with age. Saikosaponins are analgesic, antipyretic as well as antitussive; anti-inflammatory on oral administration. In Japan and China, roots have been used traditionally in auto-immune diseases. Saikosaponins form an ingredient of antitumour pharmaceuticals. A watersoluble crude polysaccharide fraction, prepared from the root, was reported to prevent HCl/ethanol-induced ulcerogenesis in mice significantly. Saikosaponin-d, at a concentration of more than 5 μm, inactivated measles virus and herpes simplex virus at room temperature. Several sterols, possessing metabolic activities and plasma cholesterollowering activity, have also been isolated from the root.

4. Comparative Genus & Family Pharmacognosy

Within Indian medicinal flora, Bupleurum flacutum stands as a distinct representative of the genus Bupleurum. Its therapeutic profile underscores the role of selectively utilized medicinal genera alongside larger polytypic genera.

At the family level, Umbelliferae encompasses 42 documented medicinal species (2.32% of the 1,814-species flora). Other representative medicinal members of Umbelliferae include: Ammi majus (Biship’s Weed-Amee), Ammi visnaga (Khella), Anethum sowa (Shataahvaa. Shatapushpaa), Angelica archangelica himalaica (Chandaa), Apium graveolens (Ajmodaa). In comparative pharmacognosy, evaluating species within the same botanical family aids quality control, authentication of crude drugs, and identification of chemotaxonomic markers.

image1

Figure 1: Quantitative documentation profile across all 42 medicinal species of family Umbelliferae.

5. Pharmacopoeial Standards, Posology & Reference Framework

In clinical and traditional dispensing, preparation and administration of Bupleurum flacutum follow the plant-part modalities specified under its therapeutic action (Roots—anti-inflammatory, haemolytic, antipyretic. Used in inflammations, muscle stiffness, neurosis, pain and pyrexia. Roots resolve inflammations of costal margin and diaphragm), guided by the standard posological principles of The Ayurvedic Pharmacopoeia of India (Vols. I–IV) and CCRAS formularies. Classical and modern pharmacognostic synchronization for Bupleurum flacutum integrates standards from The Ayurvedic Pharmacopoeia of India, The National Formulary of Unani Medicine, Formulary of Siddha Medicine, The Wealth of India (CSIR), Compendium of Indian Medicinal Plants (CDRI), Dictionary of Indian Medicinal Plants (CIMAP), German Commission E, ESCOP, WHO monographs, British Herbal Pharmacopoeia, and Natural Medicines Comprehensive Database.

Scroll to Top